Cargando…
Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
Leptomeningeal carcinomatosis is a fatal manifestation of metastatic breast cancer. Investigation of intrathecal (IT) trastuzumab for leptomeningeal carcinomatosis is currently underway; however, there has been no consensus. We report on two cases of human epidermal growth factor receptor 2 positive...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843730/ https://www.ncbi.nlm.nih.gov/pubmed/25761487 http://dx.doi.org/10.4143/crt.2014.234 |
_version_ | 1782428676548198400 |
---|---|
author | Park, Won-Young Kim, Han-Jo Kim, Kyoungha Bae, Sang-Byung Lee, Namsu Lee, Kyu-Taek Won, Jong-Ho Park, Hee-Sook Lee, Sang-Cheol |
author_facet | Park, Won-Young Kim, Han-Jo Kim, Kyoungha Bae, Sang-Byung Lee, Namsu Lee, Kyu-Taek Won, Jong-Ho Park, Hee-Sook Lee, Sang-Cheol |
author_sort | Park, Won-Young |
collection | PubMed |
description | Leptomeningeal carcinomatosis is a fatal manifestation of metastatic breast cancer. Investigation of intrathecal (IT) trastuzumab for leptomeningeal carcinomatosis is currently underway; however, there has been no consensus. We report on two cases of human epidermal growth factor receptor 2 positive (HER2+) breast cancer following IT trastuzumab for leptomeningeal carcinomatosis. The first patient was treated with weekly IT 15 mg methotrexate plus IT 50 mg trastuzumab for 7 months, followed by IT trastuzumab (50 mg > 25 mg) for 18 months. The other patient received IT trastuzumab with systemic chemotherapy (trastuzumab and/or paclitaxel) for 13 months. Good control of leptomeningeal disease was achieved with IT trastuzumab in both patients, with survival durations of 20 and 29 months, respectively. We suggest that IT trastuzumab is a promising treatment for patients with HER2+ breast cancer and leptomeningeal carcinomatosis. |
format | Online Article Text |
id | pubmed-4843730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Korean Cancer Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-48437302016-05-06 Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis Park, Won-Young Kim, Han-Jo Kim, Kyoungha Bae, Sang-Byung Lee, Namsu Lee, Kyu-Taek Won, Jong-Ho Park, Hee-Sook Lee, Sang-Cheol Cancer Res Treat Case Report Leptomeningeal carcinomatosis is a fatal manifestation of metastatic breast cancer. Investigation of intrathecal (IT) trastuzumab for leptomeningeal carcinomatosis is currently underway; however, there has been no consensus. We report on two cases of human epidermal growth factor receptor 2 positive (HER2+) breast cancer following IT trastuzumab for leptomeningeal carcinomatosis. The first patient was treated with weekly IT 15 mg methotrexate plus IT 50 mg trastuzumab for 7 months, followed by IT trastuzumab (50 mg > 25 mg) for 18 months. The other patient received IT trastuzumab with systemic chemotherapy (trastuzumab and/or paclitaxel) for 13 months. Good control of leptomeningeal disease was achieved with IT trastuzumab in both patients, with survival durations of 20 and 29 months, respectively. We suggest that IT trastuzumab is a promising treatment for patients with HER2+ breast cancer and leptomeningeal carcinomatosis. Korean Cancer Association 2016-04 2015-03-02 /pmc/articles/PMC4843730/ /pubmed/25761487 http://dx.doi.org/10.4143/crt.2014.234 Text en Copyright © 2016 by the Korean Cancer Association This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Park, Won-Young Kim, Han-Jo Kim, Kyoungha Bae, Sang-Byung Lee, Namsu Lee, Kyu-Taek Won, Jong-Ho Park, Hee-Sook Lee, Sang-Cheol Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis |
title | Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis |
title_full | Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis |
title_fullStr | Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis |
title_full_unstemmed | Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis |
title_short | Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis |
title_sort | intrathecal trastuzumab treatment in patients with breast cancer and leptomeningeal carcinomatosis |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843730/ https://www.ncbi.nlm.nih.gov/pubmed/25761487 http://dx.doi.org/10.4143/crt.2014.234 |
work_keys_str_mv | AT parkwonyoung intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis AT kimhanjo intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis AT kimkyoungha intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis AT baesangbyung intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis AT leenamsu intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis AT leekyutaek intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis AT wonjongho intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis AT parkheesook intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis AT leesangcheol intrathecaltrastuzumabtreatmentinpatientswithbreastcancerandleptomeningealcarcinomatosis |